cyrilzakka/clinical-trials huggingface dataset:
Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.

Bladder carcinoma has become a common cancer globally, Incidence rates are highest in Europe, the United States and Egypt. In Egypt, bladder carcinoma was considered the third most common tumor; Egyptian males have the highest mortality rates. UC of the urinary bladder represents about 90% of all bladder cancers.

CXCL5 is a chemokine, belonging to ‗ELR+' subgroup. It plays an important role in angiogenesis and tumor migration. Numerous reports have indicated that CXCL5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation, migration and spread is needed.

Eligibility Criteria:
Inclusion Criteria:Patients with primary invasive and non-invasive urinary bladder urothelial carcinomas.

-

Exclusion Criteria:

* - Patients received pre-operative chemotherapy or radiotherapy.
* Patients with insufficient clinical data.
* Specimens with extensive necrosis
* Tiny specimens which are insufficient for accurate diagnosis.
24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population

A database (Snapfish) has been generated at Sensimed compiling all data acquired up to now on healthy volunteers and patients with glaucoma. However, healthy subjects were much younger than glaucoma patients. Additionally, the number of glaucoma patients in Snapfish database was almost twice higher than the number of healthy subjects. As it is generally accepted that intra ocular pressure (IOP) in the aging population is higher than IOP in young adults it is of interest to evaluate the 24-hour IOP pattern of older healthy subjects. Furthermore, improving our knowledge of the "healthy" 24-hour IOP pattern in comparison to glaucoma profiles would be beneficial for management of glaucoma.


Eligibility Criteria:
Inclusion Criteria:

* Subject of Caucasian origin
* Healthy subject without previous ocular disease
* Aged between 40 and 80 years, of either sex
* Not more than 6 diopters spherical equivalent in the study eye
* Having given written informed consent, prior to any investigational procedures

Exclusion Criteria:

* Corneal or conjunctival abnormality precluding contact lens adaptation
* Previous refractive surgery
* Occludable or closed iridocorneal angle
* Sleep apnea syndrome
* Subjects with allergy to corneal anesthetic
* Subjects with contraindications for silicone contact lens wear
* Subjects not able to understand the character and individual consequences of the investigation
* Participation in other clinical research within the last 4 weeks
Proteomic and Physiological Markers of Exercise-induced Physiological Stress and Fatigue in Grand Tour Cycling

This project aims to identify the effect of a 3-week grand tour (e.g. Tour de France) on physiological markers and the blood proteome in world-class cyclists.

Blood samples will be collected in world-tour cyclists in the fasted state (i) before, (ii) on the first resting day, (ii) on the second resting day, and (iv) on the final day of the Tour de France. Samples collected before and on the final day will be analyzed by proteomics, while sample from all timepoints will be assessed for specific cytokines to identify physiological markers of fatigue. In addition, questionnaires will be used to evaluate subjective feelings of fatigue and appetite.

Eligibility Criteria:
Inclusion Criteria:

* Cyclist participating in the Tour de France

Exclusion Criteria:

* Younger than 18years old
Effect of Kangaroo Mother Care on Oxidative Stress and Bonding

The goal of this clinical trial is to learn if Kangaroo Mother care can have effect on oxidative stress in premature neonates. It will also learn about the bonding between mother and her premature infant. The main questions it aims to answer are:

* Does Kangaroo mother care lower the biomarker of oxidative stress in premature neonates?
* Is Kangaroo mother care associated with mother-infant bonding? Researchers will compare Kangaroo mother care to Conventional incubator care to see if Kangaroo mother care works to have effect on oxidative stress.

Participants will be:

* given Kangaroo mother care on third day of life or standard incubator care for one hour
* Urine sample for oxidative stress biomarker will be collected via noninvasive method before and after Kangaroo mother care or conventional incubator care from premature neonates.
* Mother-infant bonding scale will be filled by mothers of enrolled premature infants before and after kangaroo mother care and conventional incubator care

Researcher will follow existing guidelines for shifting of infant from incubator to the mother's chest. The researcher will assist the mothers to have the baby from the incubator and to sit in the special KMC chair and bed. Urine will be collected from premature infants before and after KMC/Incubator care on third day of life by applying urine collection bag. This method is highly successful in collecting urine non-invasively. Collected urine is then placed in ice box till transportation to lab at University of Health sciences(UHS). and stored at -80 °C. After completion of data collection enzyme-linked immunosorbent assay ELISA kit of Oxidative stress biomarker (Allantoin) will be used for checking level of Allantoin in stored samples within a week. Mothers of both the KMC and control groups will be given the Mother-infant bonding scale (MIBS) self-rating instrument on 3rd Day postpartum before and after KMC and incubator care for bonding assessment.

Eligibility Criteria:
Inclusion Criteria:

* For Pre-term Neonates:

  1. 24-36 weeks' gestation Premature infants
  2. Medically stable as determined by a Score of Neonatal Acute Physiology \& Perinatal Extension (SNAPPE-II); pre-term neonates with score of less than 9.
  3. Both gender
  4. Weight 1.5kg to 2.499 kg

For Mothers of Pre-term Neonates:

1. Medically stable Mothers.

Exclusion criteria:

The criteria for exclusion will be as follows:

For Pre-term Neonates:

Those will be excluded who are with below given conditions:

1. Require any kind of surgery.
2. Intraventricular hemorrhage (IVH) \> or equal to grade 3.
3. On medication such as morphine, fentanyl, midazolam, muscle relaxants, phenobarbital.
4. Severe cyanotic heart disease or severe RDS.
5. Abdominal wall or intestinal anomaly or injury.
6. Chromosomal Disorder
7. Facial anomaly.

For Mothers of Pre-term Neonates:

1. Mothers having Complications of delivery like Post partem hemorrhage.
2. Any acute illness
3. Complicated cesarean section
Treatment With Copper in Patients With Mild Alzheimer´s Dementia

The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild Alzheimer´s dementia.


Eligibility Criteria:
Inclusion Criteria:

* male or female patients
* between 50 and 80 years
* criteria of mild dementia
* probable Alzheimer´s dementia according to NINCDS-ADRDA criteria
* given written informed consent
* having a relative who can fill out questionnaire; caregiver consent
* free of serious and unstable somatic illness

Exclusion Criteria:

* unable to give informed consent
* unable to take cholinesterase inhibitors
* unapproved medication
* moderate to severe Alzheimer´s disease
* dementia of other etiology
* history of alcohol, drug or medication abuse
* other psychiatric disorder, e. g. schizophrenia
* known copper and zinc storage disease
* known copper and zinc intolerance
* vegans
* known severe allergies or intolerances
* insufficient knowledge of the German language
* female patients of childbearing potential, pregnant or nursing patients
* participation in a clinical trial within the past 30 days before onset of this study
* severe somatic diseases and high mortality rate AST, ALT, GGT, GLDH, AP or bilirubin being a two-fold above the normal range
Reconstruction of Hand and Upper Extremities Defects by Thin Random Pedicle Abdominal Flaps, Still a Valid Option in Developing Countries: A Cross Sectional Study

Traumatic defects of the soft tissues of the hand and upper extremities are common and may be challenging to the reconstructive surgeon. Several reconstructive procedures have been described to manage these defects, including local, regional, distant, and free flaps. The aim of this study is to report the techniques, outcomes, and complications of pedicle abdominal flaps in reconstructing hand and upper extremity defects. We included patients with different traumatic defects in the hand and upper extremities who underwent reconstruction by random pedicle abdominal flaps between 2002 and 2017. Data was collected and analyzed, variables studied included; patient age and sex, etiology and size of the defect, complications, outcomes, and the need for further revision procedures. Potential factors affecting flap survival were examined using appropriate statistical analysis.

Traumatic soft tissue defects of the hand and upper extremity are common and may be challenging to the reconstructive surgeon, especially when they are severe and associated with exposed vital structures such as tendons, nerves, bones, and joints. Although these defects are rarely lethal; they are invariably resource demanding, and a source of significant long-term disability. Several reconstructive procedures have been described to cover hand and upper extremities soft tissue defects, including local, regional, distant, and free flaps. Traditionally, pedicle abdominal flaps, whether axial or randomly based, have been considered the standard for successful upper limb reconstruction.

With the introduction of microsurgery in the seventies of the last century, microsurgical free tissue transfers have become the gold standard for upper extremities functional reconstruction. Free flaps and other microsurgical techniques have been used to achieve early, functional, custom-tailored reconstructive solutions for upper limbs injuries. However, despite the superiority of free flaps, this option may not be always accessible especially in developing countries, owing to the high cost and technical demands. Moreover, they may be contraindicated in certain circumstances. In these situations, pedicle abdominal flaps may once again come into the light as an alternative option for safe and effective upper extremities reconstruction.

At Jordan University Hospital, with limited microsurgical facilities, the investigators have been using random pedicle abdominal flaps in patients with different traumatic hand and upper extremities defects. The aim of this retrospective study is to report the investigator's experience in using this technique, in regards to the indications, complications, outcomes, and evaluating factors affecting flap survival rate.

Eligibility Criteria:
Inclusion Criteria:

* different traumatic defects in the hand and upper extremities who underwent reconstruction by random pedicle abdominal flaps

Exclusion Criteria:

* Patients with incomplete data about the patient and the surgery
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

Eligible subjects will be randomized in a 1:1:1 ratio to receive either ABP 206, Food and Drug Administration (FDA)-licensed nivolumab, or European Union (EU)-authorized nivolumab.

The treatment period is in alignment with the maximum treatment duration for OPDIVO® (nivolumab, reference product) in the adjuvant setting for melanoma.

All subjects will be treated until recurrence of disease, unacceptable toxicity, or subject withdrawal of consent with a maximum of 1 year of treatment.

The total duration of study participation for each subject will be approximately 13 months.

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Completely removed melanoma by surgery performed within 12 weeks of randomization
* Advanced Melanoma
* Tumor tissue from the resected site of the disease must be available for biomarker analyses in order to be randomized
* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

* Previous anti-cancer treatment
* Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug
* Ocular or uveal melanoma or history of carcinomatosis meningitis
* History of auto-immune disease
* Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of the investigational product

Other protocol-defined inclusion/exclusion criteria apply
Optimization of Health Expenditure in Liver Surgery

The aim of this study is to reduce the length of stay after liver surgery by taking account of objective quantitative clinical variables, subjective qualitative clinical variables and non clinical variables.

a new dimension of the activity expected of physicians is to improve the safety of care on the one hand and the control of health care costs on the other.

key measures to help them are the publication of national recommendations, assessment of actual practices and the incentive to activity.

Internationalwide recent and concordant data suggest that

* quality and security of care, after an initial improvement, are going to stall
* scientific recommendations are rarely validated by an impact analysis and are not applied
* clinical data collected within an administrative framework are unreliable and too generalist
* the evaluation, especially in the surgical field, is based on indicators sometimes irrelevant and often unclear

Eligibility Criteria:
Inclusion Criteria:

* elective liver surgery
* older than 18
* agreed to participate
* surgical procedure included procedures registered as "HLFA003 - 007 ; 009 - 011 ; 017 - 020 ; HLFC002 à 004 ; 027 ; 032 ; 037" in the PMSI database

Exclusion Criteria:

* emergency surgery
* refused to participate
Comparison of the Effects of QLB 2 and QLB 3 on Post-operative Analgesia in Cesarean Section Surgery

This study evaluates the post-operative analgesic effects of quadratus lomborum block 2 and 3 (QLB 2, 3) in patients having cesarean section with spinal anesthesia. Spinal anesthesia will be performed to all patients for the surgery.

In this study, patients are divided into two groups. After the spinal anesthesia is performed and cesarean section surgery is over; QLB 2 block will be performed to patients in Group A ; while QLB 3 block will be performed to patients in Group B.

In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Group A - Patients in group A will have QLB 2 block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Group B - Patients in group B will have QLB 3 block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Being pregnant for at least 37 weeks
* Planning an elective cesarean operation
* Being between the ages of 18-45

Exclusion Criteria:

* ASA 3-4 patients with comorbitidies (Serious renal, cardiac, hepatic disease)
* Being operated with general anesthesia
* Obesity (\> 100 kg, BMI\> 35 kg / m2)
* Contraindication of regional anesthesia (quagulopathy, abnormal INR, thrombocytopenia, infection at the injection site)
* Hypersensitivity to local anesthetics or a history of allergy
* Patients with a history of opioid use longer than four weeks
* Patients with psychiatric disorders
* Patients with anatomic deformity
* Patients who do not want to participate
An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of aerosol pentamidine when used as a prophylactic agent in patients who have had at least two or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP).


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Zidovudine (AZT).
* Standard or experimental treatments for an opportunistic infection or neoplasm (including aerosolized or intravenous pentamidine) that develops during the study.

Concurrent Treatment:

Allowed:

* Any standard or experimental treatment for an opportunistic infection or neoplasm that develops during the study.

Patients must have AIDS with at least one cytologically or histologically proven episode of Pneumocystis carinii pneumonia (PCP).

* Patients must be free of acute medical problems.

Prior Medication:

Allowed:

* Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Requiring ongoing active therapy for an opportunistic infection at the time of study entry.
* Toxoplasmosis.
* Cryptococcus.
* Pulmonary Kaposi's sarcoma (KS).
* Asthma poorly controlled by medication.

Concurrent Medication:

Excluded:

* Pentamidine by any route other than aerosolized or intravenous or any other experimental agent for chemoprophylaxis of PCP while on the study (e.g.:
* Septra, Fansidar, Dapsone, or eflornithine).

Concurrent Treatment:

Excluded:

* Transfusion dependency defined as \> 1 blood transfusion per month.

Patients with the following are excluded:

* Requiring ongoing active therapy for an opportunistic infection (O.I.) at the time of entry or having either Toxoplasmosis or cryptococcosis at entry.
* Pulmonary Kaposi's sarcoma (KS).
* Active substance abuse by patients who cannot comply with study procedures.
* Unwilling to sign informed consent.
* In the opinion of the investigator cannot cooperate with study procedure.
* Asthma poorly controlled by medication.
* Patients may not receive pentamidine by any other route than aerosolized or intravenous or any other experimental agent for chemoprophylaxis of PCP while on the study (e.g.:
* Septra, Fansidar, Dapsone, or eflornithine).

Prior Medication:

Excluded within 30 days of study entry:

* Antiretroviral agents, excluding zidovudine (AZT).
* Immunomodulating agents.
* Corticosteroids.

Prior Treatment:

Excluded within 7 days of study entry:

* Blood transfusion.
* Excluded:
* Requiring ongoing active treatments for an opportunistic infection at time of study entry.

Active substance abuse by patients who cannot comply with study procedures.
Short-course Antibiotic Treatment in AECOPD: a Meta-analysis of Double-blind Studies

Chronic obstructive pulmonary disease (COPD) is a common disease worldwide and a leading cause of death and disability globally. Given that bacteria are implicated in a substantial proportion of acute exacerbation of COPD (AECOPD), antibiotics are frequently used. However, this current practice may lead to antibiotic overuse further increasing drug resistance and side effects. Although the small literature on interventions to prove the effective of short course of antibiotic, a metaanalysis of published randomised double-blind studies comparing the same antibiotics compared to a previous study is performed to determine whether a short course of antibiotic treatment is as effective as a very short course in patients with an exacerbation of COPD (EACOPD). The authors systematically searched electronic databases on the literature of controlled trials on Medline and Embase with no language, location, or time restrictions. The authors retrieved observational and controlled trials comparing different durations of the same oral antibiotic therapy in the treatment of acute exacerbations of COPD. The authors included 30 randomized, placebo-controlled trials for COPD patients. There was no statistically significant difference between shorter and longer antibiotic courses in early clinical success. In conclusion, Short-course antibiotic treatment is as effective as very short-course treatment in patients with mild to moderate exacerbations of chronic bronchitis and COPD.


Eligibility Criteria:
Inclusion Criteria:

* Studies considered eligible for inclusion were randomised trials of antibiotic intervention involving adult patients \>18 years of age with a diagnosis of AECOPD.

Exclusion Criteria:

* Studies not published in the English language or with more than two or different antibiotics were excluded
Connective Tissue Grafting for Single Tooth Recession & the Impact of the Thickness of the Palatal Harvest Tissue

The purpose of this study is to test if the thickness of the graft taken from the roof of the mouth, has a significant effect on the amount of attached tissue and the amount of root coverage that are attained when treating a single tooth with gingival recession.

The goal of the study is to determine if the thickness of a tissue graft taken from the roof of the mouth, used to cover the exposed root of a tooth, affects the overall outcome of the root coverage, the health of the resulting tissue, as well as postoperative pain as reported by the patient. Connective tissue grafts will be harvested in different thicknesses, and results of the procedures will be compared. Qualified subjects will undergo a root coverage procedure, after random assignment to one of the groups. Regular recall visits to monitor healing at intervals of 1 week, 2 weeks, 1 month, and 3 months will be scheduled. Subjects will be asked to fill out patient response forms regarding pain and other symptoms at these visits. Photographs will be taken.

Eligibility Criteria:
Inclusion Criteria:

1. Age\>18 years old
2. Absence of active periodontal disease
3. Single tooth (premolars and anterior teeth) with Miller class I or II gingival recession \>= 2mm
4. Detectable Cemento-Enamel Junction (CEJ) -

Exclusion Criteria:

1. Smokers (\>10 cigarettes/ per day)
2. Uncontrolled systemic diseases with compromised healing potential (DM with HbA1c \>7%)
3. Active infectious diseases (hepatitis, tuberculosis, HIV, etc.)
4. Medication known to cause gingival enlargement
5. Patients taking anticoagulants with an international normalized ratio (INR) \>2.5
6. Long-term (\>2 weeks) use of antibiotics in the past 3 months
7. Pregnant or attempting to get pregnant
8. Sites with probing depth \> 4mm
9. Recession adjacent to an edentulous area
10. Frenal and muscle attachment that encroach on the marginal gingiva

    a. Can be included 2 months after surgical therapy to remove the frenum (frenectomy)
11. History of periodontal surgical treatment of the involved sites
12. Prosthetic crown, restorations or caries in the candidate tooth and adjacent teeth
13. Teeth with pulpal pathology
14. Severe teeth malposition and open contacts
15. Planned orthodontic treatment to commence within 1 year following procedure
16. Parafunctional habits -